BPC40: BPC40 group with 40 g/kg of BPC-157
In rodent models, BPC-157 demonstrated a wide therapeutic index with no observed hepatotoxicity, nephrotoxicity, or neurotoxicity across multiple dosing regimens. Sikiric et al., Regenerative Pharmacology Reported Side Effects (Rare) While side effects are rare, some users report: Peptides like BPC-157 generally exhibit low immunogenicity and low systemic toxicity, though user-specific variables such as injection technique or gut sensitivity may influence short-term side effects. [Clinical Peptide Society Review, 2021] Is BPC-157 Safe for Long-Term Use
PMID: 18061177 PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation Guillaume Dalmasso, Laetitia Charrier-Hisamuddin, Hang Thi Thu Nguyen, Yutao Yan, Shanthi Sitaraman, and Didier Merlin ~ Inflamm Bowel Dis
However, in a randomized phase III double-blind clinical trial, tivantinib did not improve OS time in patients with Met-high advanced HCC treated with sorafenib compared with placebo (Rimassa et al., 2018) (NCT01755767)